TapImmune Inc. (NASDAQ:MRKR) saw strong trading volume on Friday . 711,100 shares changed hands during trading, an increase of 54% from the previous session’s volume of 460,779 shares.The stock last traded at $5.90 and had previously closed at $5.81.
A number of research analysts have recently weighed in on the company. Janney Montgomery Scott reaffirmed a “buy” rating on shares of TapImmune in a research report on Sunday, July 21st. Oppenheimer assumed coverage on TapImmune in a research report on Wednesday, July 3rd. They set an “outperform” rating and a $15.00 price objective on the stock. Roth Capital assumed coverage on TapImmune in a research report on Thursday, May 30th. They set a “buy” rating and a $10.00 price objective on the stock. Nomura reaffirmed a “buy” rating and set a $16.00 price objective on shares of TapImmune in a research report on Tuesday, August 13th. Finally, ValuEngine cut TapImmune from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $10.21.
The firm has a 50 day moving average of $5.05 and a 200-day moving average of $5.96. The company has a market cap of $269.46 million, a P/E ratio of -3.53 and a beta of 0.28. The company has a current ratio of 16.85, a quick ratio of 16.85 and a debt-to-equity ratio of 0.01.
In other TapImmune news, insider Peter L. Hoang bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were bought at an average price of $4.62 per share, with a total value of $46,200.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 23.70% of the stock is currently owned by company insiders.
About TapImmune (NASDAQ:MRKR)
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Read More: How to invest in blue-chip stocks
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.